InvestorsHub Logo
Followers 4053
Posts 151055
Boards Moderated 3
Alias Born 08/05/2009

Re: TheFinalCD post# 4004

Thursday, 06/09/2016 7:10:19 PM

Thursday, June 09, 2016 7:10:19 PM

Post# of 12115
Gevo Announces Proposed Public Offering of Common Stock


Gevo, Inc. (MM) (NASDAQ:GEVO)
Intraday Stock Chart
Today : Thursday 9 June 2016

Click Here for more Gevo, Inc. (MM) Charts.

Gevo, Inc. (NASDAQ:GEVO), a leading renewable chemicals and next-generation biofuels company, announced today that it intends to offer and sell shares of common stock, subject to market and other conditions. The shares of common stock are to be sold by Gevo, subject to market and other conditions, in a best efforts public offering.
Gevo currently intends to use the net proceeds from the offering to fund working capital and for other general corporate purposes.

In connection with the offering, Cowen and Company, LLC is acting as sole book-running manager and representative of the several placement agents participating in the offering, and Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC, is acting as lead manager.

A shelf registration statement relating to the shares of common stock to be issued in the proposed offering was filed with the Securities and Exchange Commission (SEC) and is effective. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

Gevo, Inc.
This prospectus supplement (“Prospectus Supplement”) modifies, supersedes and supplements information contained in, and should be read in conjunction with, that certain prospectus, dated May 15, 2013, as supplemented by the prospectus supplements dated December 8, 2015 and March 29, 2016, which together form a part of a registration statement filed by Gevo, Inc. (the “Company”) with the U.S. Securities and Exchange Commission utilizing a “shelf” registration process (the “Prospectus”).
This Prospectus Supplement may add or update information contained in the Prospectus and the documents incorporated by reference therein. To the extent that any statement we make in this Prospectus Supplement is inconsistent with statements made in the Prospectus or any documents incorporated by reference therein, the statements made in this Prospectus Supplement will be deemed to modify or supersede those made in the Prospectus and such documents incorporated by reference therein. We may amend or supplement the Prospectus from time to time by filing amendments or supplements as required. You should read the entire Prospectus and any amendments or supplements carefully before you make an investment decision.
This Prospectus Supplement is not complete without, and may not be delivered or utilized except in connection with the Prospectus, including any amendments or supplements thereto.
As permitted by Section 2(a) of the Series H Warrants to Purchase Common Stock (the “Series H Warrants”), on Tuesday, June 7, 2016, the board of directors of the Company approved a voluntary reduction of the exercise price for 3,000,000 of the outstanding Series H Warrants, from the current exercise price of $0.75 per share of common stock to $0.42 per share of common stock, for the remaining term of these warrants. Except for the reduction in exercise price, the terms of these Series H Warrants remain unchanged.
In addition, as permitted by Section 2(a) of the Series H Warrants to Purchase Common Stock, on Tuesday, June 7, 2016, the board of directors of the Company also approved a voluntary reduction of the exercise price for 2,000,000 of the outstanding Series H Warrants, from the current exercise price of $0.75 per share of common stock to $0.52 per share of common stock, for the remaining term of these warrants. Except for the reduction in exercise price, the terms of these Series H Warrants remain unchanged.
The board of directors of the Company reserves the right, in accordance with the terms of the Series H Warrants, to reduce the exercise price of all or any portion of the Series H Warrants to any amount deemed appropriate by the board of directors of the Company, in its sole discretion.
As permitted by Section 9 of the Series D Warrants to Purchase Common Stock (the “Series D Warrants”), on Wednesday, June 8, 2016, the Company agreed with certain holders of the Series D Warrants to the amendment of the exercise price and the acceleration of the initial exercise date for 4,167,391 of the outstanding Series D Warrants held by such holders. Pursuant to that amendment agreement, with respect to 4,167,391 of the outstanding Series D Warrants held by those holders,

the exercise price was increased from the current exercise price of $0.10 per share of common stock to $0.175 per share of common stock, for the remaining term of these warrants and the initial exercise date was changed from June 11, 2016 to June 8, 2016

. Except for the change in exercise price and the initial exercise date, the terms of these Series D Warrants remain unchanged.

Our common stock is traded on the NASDAQ Capital Market under the symbol “GEVO.” On Monday, June 6, 2016, the last reported sale price of our common stock on the NASDAQ Capital Market was $0.40 per share. The Series H Warrants and the Series D Warrants are not and will not be listed for trading on the NASDAQ Capital Market, or any other securities exchange.

Always consult an Investment Professional, my posts are my own opinions, and not for investing decisions

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GEVO News